Kardigan, Inc. (KARD)
14.87
+0.08
(+0.54%)
USD |
NASDAQ |
Oct 05, 12:50
Kardigan Enterprise Value : 798.14M for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 798.14M |
| October 01, 2026 | 747.67M |
| September 30, 2026 | 794.40M |
| September 29, 2026 | 785.99M |
| September 28, 2026 | 797.21M |
| September 25, 2026 | 798.14M |
| September 24, 2026 | 760.76M |
| September 23, 2026 | 772.91M |
| September 22, 2026 | 952.36M |
| September 21, 2026 | 939.28M |
| September 18, 2026 | 971.06M |
| September 17, 2026 | 975.73M |
| September 16, 2026 | 1.034B |
| September 15, 2026 | 1.151B |
| September 14, 2026 | 1.196B |
| September 11, 2026 | 1.147B |
| September 10, 2026 | 1.163B |
| September 09, 2026 | 1.255B |
| September 08, 2026 | 1.435B |
| September 04, 2026 | 1.365B |
| September 03, 2026 | 1.354B |
| September 02, 2026 | 1.465B |
| September 01, 2026 | 1.248B |
| August 31, 2026 | 1.300B |
| August 28, 2026 | 1.287B |
| Date | Value |
|---|---|
| August 27, 2026 | 1.360B |
| August 26, 2026 | 1.395B |
| August 25, 2026 | 1.371B |
| August 24, 2026 | 1.345B |
| August 21, 2026 | 1.380B |
| August 20, 2026 | 1.309B |
| August 19, 2026 | 1.473B |
| August 18, 2026 | 1.371B |
| August 17, 2026 | 1.337B |
| August 14, 2026 | 1.304B |
| August 13, 2026 | 1.454B |
| August 12, 2026 | 1.451B |
| August 11, 2026 | 1.478B |
| August 10, 2026 | 1.386B |
| August 07, 2026 | 1.332B |
| August 06, 2026 | 1.319B |
| August 05, 2026 | 1.308B |
| August 04, 2026 | 1.331B |
| August 03, 2026 | 1.282B |
| July 31, 2026 | 1.362B |
| July 30, 2026 | 1.329B |
| July 29, 2026 | 1.260B |
| July 28, 2026 | 1.378B |
| July 27, 2026 | 1.400B |
| July 24, 2026 | 1.354B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Johnson & Johnson | 644.86B |
| ANI Pharmaceuticals, Inc. | 1.893B |
| Corcept Therapeutics, Inc. | 12.24B |
| Veru, Inc. | 19.69M |
| Eli Lilly & Co. | 1.122T |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -116.24M |
| Total Expenses (Quarterly) | 116.24M |
| EPS Diluted (Quarterly) | -1.244 |
| Earnings Yield | -18.26% |
| Normalized Earnings Yield | -15.87 |